Safety and efficacy of MEDI0457 and Durvalumab in participants with Human Papilloma Virus (HPV) associated recurrent/metastatic head and neck cancer

Trial Identifier: D8860C00005
Sponsor: MedImmune, LLC
NCTID:: NCT03162224
Start Date: June 2017
Primary Completion Date: March 2021
Study Completion Date: March 2021
Condition: Head and Neck Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version
Spanish Translation

Trial Locations

Country Location
US, CA San Francisco, CA, US, 94115
US, FL Orlando, FL, US, 32806
US, GA Atlanta, GA, US, 30308
US, IN Indianapolis, IN, US, 46202
US, MD Baltimore, MD, US, 21287
US, MD Baltimore, MD, US, 21201
US, MI Detroit, MI, US, 48201
US, MN Minneapolis, MN, US, 55414
US, MO Saint Louis, MO, US, 63110
US, NC Winston-Salem, NC, US, 27157
US, NJ Morristown, NJ, US, 07960
US, NY Bronx, NY, US, 10461
US, OH Columbus, OH, US, 43210
US, PA Philadelphia, PA, US, 19104